AbbVie Inc.ABBVNYSE
Loading

Latest News

February Dividends With 4 Raises: 1.6% Up To 14.5%
seekingalpha.com

February Dividends With 4 Raises: 1.6% Up To 14.5%

Rose's Income Garden portfolio reached an all-time high, with forward yield dipping slightly to 6% as portfolio value increased. Mastercard stands out with a 14.5% dividend raise, attractive valuation (P/E 26.41 vs. 5-year 34.81x), and robust earnings growth, making it a core hold. Bristol Myers Squibb and AbbVie are both considered holds due to disappointing or modest dividend raises and valuations above historical norms.

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease
prnewswire.com

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for induction delivered by subcutaneous (SC) injection versus placebo1 These data support strong efficacy of risankizumab in Crohn's disease while providing potential for an induction choice for patients1 The safety profile of risankizumab SC induction was consistent with its known profile in Crohn's disease, with no new safety risks observed1 NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) subcutaneous (SC) induction treatment versus placebo in adult patients with moderately to severely active Crohn's disease (CD).1 The AFFIRM study results show significantly greater proportions of patients treated with risankizumab SC induction achieved the co-primary endpoints of Crohn's Disease Activity Index (CDAI) clinical remissiona (55% vs.

Bahl & Gaynor Inc. Has $730.34 Million Stock Holdings in AbbVie Inc. $ABBV
defenseworld.net

Bahl & Gaynor Inc. Has $730.34 Million Stock Holdings in AbbVie Inc. $ABBV

Bahl and Gaynor Inc. cut its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 23.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,154,256 shares of the company's stock after selling 968,314 shares during the period. AbbVie

The High Dividend Yield Bull Market: 3 Compelling 6% Yields
seekingalpha.com

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

High-yield stocks are outperforming, with a clear rotation from growth to value driving strong returns for dividend-focused investors. Safe, high-yielding companies are still trading at discounts. These 3 are in the process of rerating, providing an appealing position to initiate a position.

AbbVie Inc. $ABBV Shares Sold by 111 Capital
defenseworld.net

AbbVie Inc. $ABBV Shares Sold by 111 Capital

111 Capital lessened its position in AbbVie Inc. (NYSE: ABBV) by 77.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,411 shares of the company's stock after selling 15,143 shares during the period. 111 Capital's holdings in AbbVie were worth $1,021,000 at the

AbbVie Inc. $ABBV is Argent Trust Co’s 8th Largest Position
defenseworld.net

AbbVie Inc. $ABBV is Argent Trust Co’s 8th Largest Position

Argent Trust Co lowered its stake in AbbVie Inc. (NYSE: ABBV) by 1.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 205,045 shares of the company's stock after selling 3,119 shares during the period. AbbVie accounts for about 1.7% of Argent Trust

Best Dividend Aristocrats For March 2026
seekingalpha.com

Best Dividend Aristocrats For March 2026

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.

DNB Asset Management AS Lowers Holdings in AbbVie Inc. $ABBV
defenseworld.net

DNB Asset Management AS Lowers Holdings in AbbVie Inc. $ABBV

DNB Asset Management AS lowered its stake in shares of AbbVie Inc. (NYSE: ABBV) by 1.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 493,795 shares of the company's stock after selling 9,251 shares during the period. DNB Asset Management AS's holdings in AbbVie

Andra AP fonden Grows Stock Holdings in AbbVie Inc. $ABBV
defenseworld.net

Andra AP fonden Grows Stock Holdings in AbbVie Inc. $ABBV

Andra AP fonden increased its position in AbbVie Inc. (NYSE: ABBV) by 43.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,300 shares of the company's stock after purchasing an additional 32,500 shares during the period. Andra

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
seekingalpha.com

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

Merck & Co. (MRK) is upgraded to buy, driven by improving dividend cushion ratio (DCR) and robust FQ4 2025 earnings recovery. MRK's dividend safety strengthens, with a projected DCR of 2.57x for 2026, surpassing both its historical average and ABBV's outlook. AbbVie (ABBV) maintains strong results but faces DCR pressure from CAPEX plans, with a projected 2.19x DCR in 2026.

Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More
247wallst.com

Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More

Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a "Meltdown Monday." Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology... Here Are Wednesday's Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More.

AbbVie Inc. $ABBV Shares Bought by Empirical Asset Management LLC
defenseworld.net

AbbVie Inc. $ABBV Shares Bought by Empirical Asset Management LLC

Empirical Asset Management LLC increased its position in AbbVie Inc. (NYSE: ABBV) by 206.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,372 shares of the company's stock after acquiring an additional 6,986 shares during the period. Empirical